Pinosylvin

Pinosylvin

SCHEMBL675667

Oc1cc(O)cc(C=Cc2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 2/20 0.71
PTGS1 P23219 6/20 0.70
KDM4E B2RXH2 4/20 0.70
PTGS2 P35354 4/20 0.70
TTR P02766 4/20 0.70
MEN1 O00255 3/20 0.70
ALDH1A1 P00352 3/20 0.70
TP53 P04637 3/20 0.70
CYP3A4 P08684 3/20 0.70
MAPT P10636 3/20 0.70
HPGD P15428 3/20 0.70
KMT2A Q03164 3/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
HSD17B10 Q99714 3/20 0.70
LMNA P02545 3/20 0.70
CA12 O43570 2/20 0.70
CA1 P00915 2/20 0.70
CA2 P00918 2/20 0.70
CA3 P07451 2/20 0.70
CA4 P22748 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pinosylvin SCHEMBL454262 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL2237657 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL9419839 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL3940383 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL20455852 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL7075363 1.00 LCK (0.71) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL1586341 0.93 KDM4E (0.72) LCKPTGS1KDM4EPTGS2TTR
Resveratrol SCHEMBL721421 0.93 KDM4E (0.83) LCKPTGS1KDM4EPTGS2TTR
Resveratrol SCHEMBL7529004 0.93 KDM4E (0.83) LCKPTGS1KDM4EPTGS2TTR
Pinosylvin SCHEMBL27484375 0.93 KDM4E (0.72) LCKPTGS1KDM4EPTGS2TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704801-A1 COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE ELC Management LLC (US) 2026-03-11 EP claimed
CN-118948982-A Compositions comprising alpinia and other plant extracts for improving joint health and treating arthritis 尤尼根公司 2024-11-15 CN claimed
WO-2024229025-A1 COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE ELC MANAGEMENT LLC (US) 2024-11-07 WO claimed
EP-4436538-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION Merryvital AG (CH) 2024-10-02 EP claimed
US-20240263203-A1 RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES IPTECTOR ASSETS APS (DK) 2024-08-08 US claimed
CN-118401224-A Cosmetic or cosmeceutical product for skin care and improving skin condition 迈瑞维拓股份公司 2024-07-26 CN claimed
CN-117801688-A Flexible adhesive material and preparation method thereof 南通市锋芒复合材料科技有限公司 2024-04-02 CN claimed
WO-2023094852-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION MERRYVITAL AG (CH) 2023-06-01 WO claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
CN-115515614-A Compositions comprising extracts of alpinia and other plants for improving joint health and treating arthritis 尤尼根公司 2022-12-23 CN claimed
EP-2005941-A2 Cellular rejuvenation compounds Henkel AG & Co. KGaA (DE) 2008-12-24 EP claimed
US-20080139650-A1 Fungicidally Active Polymer Dispersions And Use Thereof CELANESE EMULSIONS GMBH (DE) 2008-06-12 US claimed
EP-1796459-A2 FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF Celanese Emulsions GmbH (DE) 2007-06-20 EP claimed
WO-2006034762-A2 FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF CELANESE EMULSIONS GMBH (DE) 2006-04-06 WO claimed
US-20020198159-A1 USE OF STILBENE DERIVATIVES SUBSTITUTED IN POSITION 3 AS DEODORANT ACTIVE AGENTS IN COSMETIC COMPOSITIONS L'OREAL S.A. 2002-12-26 US claimed
US-6407142-B1 APPLYING 3,5-DIHYDROXYSTILBENE TO INHIBIT CORYNEBACTERIUM L'OREAL S.A. (FR) 2002-06-18 US claimed
US-20020028852-A1 Resveratrol analogs for prevention of disease RUTGERS, THE STATE UNIVERSITY 2002-03-07 US claimed
CN-1270804-A use of diphenyl styrene in cosmetic composition as deodoring active content OREAL (FR) 2000-10-25 CN claimed
EP-1029530-A1 Use of 3-substituted stilbene derivatives as deodorizing active principles in cosmetic compositions L'OREAL (FR) 2000-08-23 EP claimed
CN-1196245-A Application of stilbene compound and its derivative in preparation of endothelium element antagonist agent AIR FORCE GENERAL HOSPITAL PLA (CN) 1998-10-21 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139650-A1 Fungicidally Active Polymer Dispersions And Use Thereof CBR3, CBR1, CYP3A4 LCK 4853/4885PTGS1 3517/4885KDM4E 1199/4885
US-20020198159-A1 USE OF STILBENE DERIVATIVES SUBSTITUTED IN POSITION 3 AS DEODORANT ACTIVE AGENTS IN COSMETIC COMPOSITIONS DDT, HAAO, HDHD5 LCK 2166/4885PTGS1 2696/4885KDM4E 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.